Clinical Trials
-
Principal Investigator:
Fabio M. Iwamoto, MDThe purpose of this study is to learn the effects of the investigational new drug, tirabrutinib, when given for the treatment of PCNSL. Investigational new drug means a drug that has not been approved as a marketed product (that is, available to be prescribed or sold) by the United States (US) Food and Drug Administration (FDA). Tirabrutinib acts by blocking an enzyme called Brutons tyrosine kinase or BTK. Some cancer cells use BTK to grow and thrive in your body. Tirabrutinib blocks BTK and may interfere with the growth of cancer cells. This study is divided into 2 parts; Part A of the study... -
Principal Investigator:
Fabio M. Iwamoto, MDThe purpose of this study is to learn the effects of the investigational new drug, tirabrutinib, when given for the treatment of PCNSL. Investigational new drug means a drug that has not been approved as a marketed product (that is, available to be prescribed or sold) by the United States (US) Food and Drug Administration (FDA). Tirabrutinib acts by blocking an enzyme called Brutons tyrosine kinase or BTK. Some cancer cells use BTK to grow and thrive in your body. Tirabrutinib blocks BTK and may interfere with the growth of cancer cells. This study is divided into 2 parts; Part A of the study... -
Principal Investigator:
Mary R. Welch, MDThe purpose of this study is to test good and bad effects of these two different drugs against meningioma tumors with altered genes. Today, therapy for meningioma is the same for all patients and is not based on tumor genetic testing. This trial is trying to see if tumor genetic testing would be helpful at guiding treatment in patients with meningioma. Researchers have looked at the DNA material (genes) that can be affected in meningioma and have found several genes that are altered, or mutated. These include the genes called SMO and NF2. When the SMO or NF2 genes are altered, it can cause a... -
Principal Investigator:
Mary R. Welch, MDThe purpose of this study is to test good and bad effects of these two different drugs against meningioma tumors with altered genes. Today, therapy for meningioma is the same for all patients and is not based on tumor genetic testing. This trial is trying to see if tumor genetic testing would be helpful at guiding treatment in patients with meningioma. Researchers have looked at the DNA material (genes) that can be affected in meningioma and have found several genes that are altered, or mutated. These include the genes called SMO and NF2. When the SMO or NF2 genes are altered, it can cause a... -
Principal Investigator:
Andrew B. Lassman, MDThe purpose of this study is to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatment(s) improve overall survival as compared to standard treatments. Investigational means that these are new treatments sometimes called study drugs and are not approved by the Food and Drug Administration (FDA) to be used for your type of cancer. The investigational treatments in this study have been previously tested in people. -
Principal Investigator:
Andrew B. Lassman, MDThe purpose of this study is to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatment(s) improve overall survival as compared to standard treatments. Investigational means that these are new treatments sometimes called study drugs and are not approved by the Food and Drug Administration (FDA) to be used for your type of cancer. The investigational treatments in this study have been previously tested in people. -
Principal Investigator:
Karen L. Bell, MDWe are seeking men and women, ages 50-85 years, who have mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia for an 18-month treatment, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to determine whether the CT1812 study drug beneficially affects cognition and function in participants. The study participant will receive MRI and PET scans, and will take an orally administered drug (or placebo) daily. -
Principal Investigator:
Giuseppe Tosto, MD, PhDThis study aims to find genes that cause Alzheimer's Disease in African Americans and Hispanics/Latinos. Participants are eligible if African American or Hispanic/Latino and 60 years of age or older. Study participation would entail completing a memory assessment, having their blood drawn, and a brief physical exam with a questionnaire. Compensation of $50 will be provided, if unable to come to Columbia University Irving Medical Center, home visits are also available. Participants can live anywhere in the US.More information at www.thedawnstudy.com -
Principal Investigator:
Philip L. De Jager, MD, PHDThe purpose of this study is to establish a collection of biological fluids and associated data from healthy individuals to determine how genetic and environmental variation affects the immune system. Study visits consist of taking vitals and collecting biological fluids, such as blood. You will be compensated for participating in this study. -
Principal Investigator:
Dritan Agalliu, PhDThe aim of this study is to understand the mechanisms of secondary effects of traumatic brain injury on the blood-brain barrier and to understand the biochemical differences in the blood of people with Alzheimer's disease and the volunteer group. We will compare biochemical blood differences between a healthy group and traumatic brain injury patients and Alzheimer's disease. Our aim is to identify biochemical changes in the blood that may worsen the prognosis in traumatic brain injury and Alzheimer's disease. We are looking for healthy volunteers in certain age groups (35-55, 60-80) who meet...